Eric Leire

About Eric Leire

Dr. Eric Leire is an international life sciences executive with extensive experience in biotechnology and the pharmaceutical industry across the United States and Europe. At OSE Immunotherapeutics, he was proposed in May 2023 as an independent board member, reflecting the company’s intention to broaden the Board’s skills and strengthen its international reach. His profile is particularly relevant to listed biotech companies because it combines operational leadership, capital markets experience, and a deep understanding of governance and value creation in highly innovative healthcare businesses. Prior to joining OSE’s governance framework, he served as President and Chief Executive Officer of Genflow Biosciences Ltd, a London-listed company focused on gene therapy and longevity-related science. He also previously held top executive roles in the United States as Chairman and then President and Chief Executive Officer of Enochian Biosciences, listed on Nasdaq and active in cell and gene therapy, HIV, and cancer, as well as DanDrit Biotech, listed on OTCQB. Earlier in his career, Dr. Leire worked in pharmaceutical marketing leadership roles at Pfizer, Schering Plough, and Boots Pharma in both the U.S. and Europe. That commercial and strategic background was complemented by hands-on exposure to healthcare venture capital through roles at Medwell Capital in Canada and Biofund Venture in Denmark. This combination gave him direct insight into how biotech ventures are financed, scaled, and positioned for growth, especially in an environment where scientific progress, investor confidence, and clinical execution must align. Dr. Leire’s academic and scientific credentials are equally notable. He is a medical doctor from Grenoble University and holds a postgraduate degree in health law from the University of Sceaux. He spent three years as a researcher at the Harvard AIDS Institute, reinforcing his scientific credibility and understanding of translational research. He also earned an MBA from HEC (ISA) and from the Kellogg Graduate School of Management in Chicago. Overall, Eric Leire represents a profile at the intersection of medicine, health law, business strategy, and biotech governance, making him a seasoned contributor to boards of innovative life sciences companies.